Suma P Shankar

Dr. Suma P Shankar


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2018 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
Dominique P. GERMAINDominique P. GERMAIN
Dominique P. GERMAIN
EBEva Brand
Eva Brand
ABAlessandro Burlina
Alessandro Burlina
FCFranco Cecchi
Franco Cecchi
SGScott C. Garman
Scott C. Garman
AJAna Jovanovic
Ana Jovanovic
Background: The p.Asn215Ser or p.N215S GLA variant has been associated with late‐onset cardiac variant of Fabry disease.Methods: To expand on the scarce phenotype data, we analyzed natural history data from 125 p.N215S patients (66 females, 59 males) enrolled in the Fabry Registry (NCT00196742) and compared it with data from 401 patients (237 females, 164 males) harboring mutations associated with classic Fabry disease. We evaluated interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT), estimated glomerular filtration rate and severe clinical events.Results: In p.N215S males, mildly abnormal mean IVST and LVPWT values were observed in patients aged 25–34 years, and values gradually increased with advancing age. Mean values were similar to those of classic males. In p.N215S females, these abnormalities occurred primarily in patients aged 55–64 years. Severe clinical events in p.N215S patients were mainly cardiac (males 31%, females 8%) while renal and cerebrovascular events were rare. Renal impairment occurred in 17% of p.N215S males (mostly in patients aged 65–74 years), and rarely in females (3%).Conclusion: p.N215S is a disease‐causing mutation with severe clinical manifestations found primarily in the heart. Cardiac involvement may become as severe as in classic Fabry patients, especially in males.

27 April 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
RSRaphael Schiffmann
Raphael Schiffmann
DBDaniel G. Bichet
Daniel G. Bichet
AJAna Jovanovic
Ana Jovanovic
DHDerralynn Hughes
Derralynn Hughes
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
KNKathleen Nicholls
Kathleen Nicholls
Fabry disease is frequently characterized by gastrointestinal symptoms, including diarrhea. Migalastat is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with amenable mutations. We evaluated minimal clinically important differences (MCID) in diarrhea based on the corresponding domain of the patient-reported Gastrointestinal Symptom Rating Scale (GSRS) in patients with Fabry disease and amenable mutations (N = 50) treated with migalastat 150 mg every other day or placebo during the phase 3 FACETS trial (NCT00925301). After 6 months, significantly more patients receiving migalastat versus placebo experienced improvement in diarrhea based on a MCID of 0.33 (43% vs 11%; p = .02), including the subset with baseline diarrhea (71% vs 20%; p = .02). A decline in kidney peritubular capillary globotriaosylceramide inclusions correlated with diarrhea improvement; patients with a reduction > 0.1 were 5.6 times more likely to have an improvement in diarrhea than those without (p = .031). Migalastat was associated with a clinically meaningful improvement in diarrhea in patients with Fabry disease and amenable mutations. Reductions in kidney globotriaosylceramide may be a useful surrogate endpoint to predict clinical benefit with migalastat in patients with Fabry disease. NCT00925301 ; June 19, 2009.

1 January 2023
Verified
Journal Article
Open access
VMVan K. Ma
Van K. Ma
RMRong Mao
Rong Mao
JTJessica N. Toth
Jessica N. Toth
MFMakenzie L. Fulmer
Makenzie L. Fulmer
AEAlena S. Egense
Alena S. Egense
SSSuma P Shankar
Suma P Shankar
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are genetic imprinting disorders resulting from absent or reduced expression of paternal or maternal genes in chromosome 15q11q13 region, respectively. The most common etiology is deletion of the maternal or paternal 15q11q13 region. Methylation is the first line for molecular diagnostic testing; MS-MLPA is the most sensitive test. The molecular subtype of PWS/AS provides more accurate recurrence risk information for parents and for the individual affected with the condition. Management should include a multidisciplinary team by various medical subspecialists and therapists. Developmental and behavioral management of PWS and AS in infancy and early childhood includes early intervention services and individualized education programs for school-aged children. Here, we compare and discuss the mechanisms, pathophy-siology, clinical features, and management of the two imprinting disorders, PWS and AS.

1 February 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Open access
HLHeather Lau
Heather Lau
NBNadia Belmatoug
Nadia Belmatoug
Patrick B. DeeganPatrick B. Deegan
Patrick B. Deegan
OGOzlem Goker-Alpan
Ozlem Goker-Alpan
ISIda V.D. Schwartz
Ida V.D. Schwartz
Ari ZimranAri Zimran
Ari Zimran
Gaucher disease (GD) may worsen during pregnancy, leading to the discussion of continuing treatment during pregnancy. We examined fetal outcomes of pregnancies reported in the Gaucher Outcome Survey, an international GD-specific registry established in 2010. A total of 453 pregnancies were reported. Most pregnancies (336/453, 74.2%) were in women who did not receive GD-specific treatment during pregnancy, while enzyme replacement therapy (ERT) was received during 117/453 (25.8%) pregnancies. No pregnancies exposed to substrate reduction therapy were reported. The percentage of normal outcomes (live birth delivered at term with no congenital abnormalities) was similar in untreated and treated pregnancies (92.9% vs. 91.4%). The percentage of spontaneous abortions in untreated pregnancies was 3.6% (95% CI, 1.9%- 6.2%) compared with 6.9% (95% CI, 3.0%-13.1%) in treated pregnancies (p=0.1866). In women who received velaglucerase alfa <1month prior to conception and/or during pregnancy, 34/36 (94.4%) pregnancies had normal outcomes and 2 (5.6%) ended in spontaneous abortion. Normal outcomes were observed in the 20 pregnancies with velaglucerase alfa exposure starting <1month prior to conception and continuing through all trimesters. These observations, in addition to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD patients.

23 August 2010 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
JHJacob Hogue
Jacob Hogue
SSSuma P Shankar
Suma P Shankar
HPHazel Perry
Hazel Perry
RPReena Patel
Reena Patel
KVKarin Vargervik
Karin Vargervik
ASAnne Slavotinek
Anne Slavotinek

28 April 2022 in Genetics in Medicine
Verified
Journal Article
Open access
SSSuma P Shankar
Suma P Shankar
KGKristin Grimsrud
Kristin Grimsrud
LLLouise Lanoue
Louise Lanoue
AEAlena Egense
Alena Egense
BWBrandon Willis
Brandon Willis
RMRachel Mahoney
Rachel Mahoney
Diphthamide is a post-translationally modified histidine essential for messenger RNA translation and ribosomal protein synthesis. We present evidence for DPH5 as a novel cause of embryonic lethality and profound neurodevelopmental delays (NDDs). Molecular testing was performed using exome or genome sequencing. A transgenic Dph5 knockin mouse (C57BL/6Ncrl-Dph5em1Mbp/Mmucd) was created for a DPH5 p.His260Arg homozygous variant identified in 1 family. Adenosine diphosphate–ribosylation assays in DPH5-knockout human and yeast cells and in silico modeling were performed for the identified DPH5 potential pathogenic variants. DPH5 variants p.His260Arg (homozygous), p.Asn110Ser and p.Arg207Ter (heterozygous), and p.Asn174LysfsTer10 (homozygous) were identified in 3 unrelated families with distinct overlapping craniofacial features, profound NDDs, multisystem abnormalities, and miscarriages. Dph5 p.His260Arg homozygous knockin was embryonically lethal with only 1 subviable mouse exhibiting impaired growth, craniofacial dysmorphology, and multisystem dysfunction recapitulating the human phenotype. Adenosine diphosphate–ribosylation assays showed absent to decreased function in DPH5-knockout human and yeast cells. In silico modeling of the variants showed altered DPH5 structure and disruption of its interaction with eEF2. We provide strong clinical, biochemical, and functional evidence for DPH5 as a novel cause of embryonic lethality or profound NDDs with multisystem involvement and expand diphthamide-deficiency syndromes and ribosomopathies.